Pulmonary arterial hypertension: an update by Hoendermis, E. S.
REVIEW ARTICLE
Pulmonary arterial hypertension: an update
E. S. Hoendermis
Published online: 15 November 2011
# The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract Pulmonary arterial hypertension (PAH), defined
as group 1 of the World Heart Organisation (WHO)
classification of pulmonary hypertension, is an uncommon
disorder of the pulmonary vascular system. It is charac-
terised by an increased pulmonary artery pressure, increased
pulmonary vascular resistance and specific histological
changes. It is a progressive disease finally resulting in right
heart failure and premature death. Typical symptoms are
dyspnoea at exercise, chest pain and syncope; further-
more clinical signs of right heart failure develop with
disease progression. Echocardiography is the key inves-
tigation when pulmonary hypertension is suspected, but
a reliable diagnosis of PAH and associated conditions
requires an intense work-up including invasive measure-
ment by right heart catheterisation. Treatment includes
general measures and drugs targeting the pulmonary
artery tone and vascular remodelling. This advanced
medical therapy has significantly improved morbidity
and mortality in patients with PAH in the last decade.
Combinations of these drugs are indicated when treat-
ment goals of disease stabilisation are not met. In
patients refractory to medical therapy lung transplanta-
tion should be considered an option.
Keywords Pulmonary arterial hypertension.Diagnostics.
Therapy.Review
Introduction
In recent years a new definition, classification and treatment
options of pulmonary hypertension (PH) were developed
and are described in the European Society of Cardiology
(ESC) guidelines of 2009 [1]. More than 30 diagnoses can
now be classified in one of the five groups of PH. The
definition of PH is set by an invasively assessed mean
pulmonary artery pressure (PAP) of ≥25 mmHg. Pulmonary
arterial hypertension (PAH) is the group 1 of the PH
classification (Table 1) and represents the type of PH in
which spectacular advances in the understanding and
treatment have been achieved in the past decade. In the
new guidelines PH on exercise was withdrawn because the
mean PAP at exercise can exceed 30 mmHg in healthy
subjects and is dependent on age and type and level of
exercise.
Classification, aetiology and prognosis
In PAH pulmonary pressure elevation has its origin in the
precapillary pulmonary vascular system. The histological
changes consist of intima and media hypertrophy, vessel
obliteration, in-situ thrombosis and development of plexiform
lesions. These histological changes are similar in all
(clinically so different) conditions combined in the PAH
group, at least at a certain stage. On the other hand
plexiform lesions are not present in any other group of
PH [2]. PAH can be subdivided into different groups.
Idiopathic PAH is a very rare condition with an
incidence of 2–6/million adult population/year [3, 4].
Most of the patients are women in the third to fourth
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disease with an untreated survival of only 2.8 years [3, 4].
When germ-line mutations are present in idiopathic
PAH, this is referred to as heritable PAH. Heritable PAH
also includes clinical familial cases with or without
identified germ-line mutations. Mutations are identified on
the transforming-growth-factor-β (TGF-β) receptor family,
such as the BMPR II gen, Alk 1 gen and endoglin gene [5].
Mutations in the BMPR II gene have been found in 20% of
IPAH patients and in 70% of familial cases. However, the
penetrance is very variable. Echocardigraphic screening of
first-degree family members is advised. Patients with
heritable PAH have an even worse outcome than IPAH
patients [6].
PAH can be associated with exposure to drugs and
toxins, especially anorectic drugs as aminorex and fenflur-
amine. Moreover, there is also a suspected association with
the use of cocaine, (meth-) amphetamines, L-tryptophan,
mitomycin C and selective serotonin reuptake inhibitors
[1].
Very common is an association of PAH with connective
tissue disease. The highest incidence of the development of
PAH is known in scleroderma patients, especially with the
CREST syndrome as scleroderma subentity (10–20%
develop PAH), followed by systemic lupus erythematosus
(SLE, 10%) [7, 8]. Patients with PAH in connective tissue
disease have a deleterious clinical course and a worse
prognosis. In those with scleroderma echocardiographic
screening is advised once a year.
Also HIV infection is one of the established risk factors
for PAH, representing approximately 7% of all new cases of
PAH in a French PAH registry [4]. The exact pathogenesis
is unknown. The viral antigens that are found in the
endothelial wall might induce pathological growth and
proliferation next to the chronic inflammatory state and
immune activation in HIV infection. The presence of PAH
in HIV patients is an independent risk factor for survival,
which is 3.6 years from the moment of diagnosis of PAH
[9, 10].
Porto pulmonary hypertension is an association of portal
hypertension and PAH. It has an incidence of 2–9% in all
patients with structural liver disease and up to 16% in
patients with advanced liver disease. However, no clear
relation between portal vein pressure, hepatic function and
development of PAH can be shown. The prognosis is poor
with a 5-year survival rate of 14% [11]. A mPAP >35 mmHg
in combination with an elevated pulmonary vascular
resistance (PVR) is regarded as an important risk factor for
liver transplantation.
PAH is common in congenital heart disease (CHD) [12]
and forms a special subgroup with essential differences
from other PAH conditions, mainly concerning clinical
course, prognosis and heterogeneity of the group. This was
taken into account in the last modification of the guidelines
by updating the clinical and anatomical-pathophysiological
classification of PAH-CHD. Increased blood flow in the
pulmonary vasculature caused by a systemic to pulmonary
shunt is a prerequisite for the development of CHD-PAH .
Additional pressure overload, as in post-tricuspid shunts
(VSD, aorto-pulmonary window, persistent ductus botalli)
accelerates this development. In the first stage the vascular
changes are reversible and therefore curable by closure of
the shunt. At a certain point of no return irreversible
damage of the pulmonary vascular system develops and the
prognosis depends on multiple factors such as associated
heart defect, location and dimension of the shunt and
correction status (closed or unclosed shunt). Patients with
closed shunts who develop PAH probably have a prognosis
similar to that in IPAH whereas patients with a large,
unrestricted open shunt finally develop reversal of the
shunt, the so-called Eisenmenger physiology, a condition
with a relatively good survival in adults but a lot of
morbidity and risks [13].
PAH associated with schistosomiasis (incidence approx-
imately 4–5%) was included in the PAH group in the last
guidelines because clinical and histological characteristics
are similar to other PAH conditions in recent studies.
Mechanisms are probably portal hypertension in hepatos-
plenic schistosomiasis and local inflammation in the
pulmonary vessels by schistosomiasis eggs. Given the
number of patients with schistosomiasis worldwide, PAH
complicating the disease can become an important issue
[14].
Chronic haemolytic anaemia such as sickle cell disease,
thalassaemia, hereditary spherocytosis, stomatocytosis, and
microangiopathic haemolytic anaemia may result in PAH.
Persistent PH of the newborn is a clinical syndrome in
which the pulmonary vascular system fails to adapt to
Table 1 Updated classification of pulmonary arterial hypertension
1. Pulmonary arterial hypertension
1.1 Idiopathic
1.2 Heritable
1.3 Drugs and toxins induced
1.4 Associated with
1.4.1 Connective tissue diseases
1.4.2 HIV infection
1.4.3 Portal hypertension
1.4.4 Congenital heart disease
1.4.5 Schistosomiasis
1.4.6 Chronic hemolytic anaemia
1.5 Persistent pulmonary hypertension of the newborn
1’ Pulmonary veno-occlusive disease / pulmonary capillary
haemangiomatosis
Neth Heart J (2011) 19:514–522 515extra-uterine circulation. It should not be mixed with
paediatric PAH which comprises a heterogenous spectrum
of diseases, IPAH and CHD-PAH being the most common
[15].
Subgroup 1’ comprises pulmonary veno-occlusive dis-
ease (PVOD) and pulmonary capillary haemangiomatosis
because histopathologically there is overlap between the
two features. They share characteristics with the PAH
group, but also show important differences as a high
incidence of negative response to advanced PAH medica-
tion [16]. So this condition has become a distinct category.
The diagnosis is challenging as there is no non-invasive test
to give a definite diagnosis. The gold standard examination
is open lung biopsy, an extremely high-risk procedure in
PAH patients.
Diagnosis
A diagnostic algorithm for the diagnosis of PH and for
classification in PAH and the other different PH groups and
subgroups is available in the current guidelines (Fig. 1). In
general, once PH is suspected, common causes have to be
diagnosed or ruled out first. The most common causes by
far are left heart disease and lung disease. If one of these
diagnoses is confirmed and the pulmonary pressure is not
exceeding moderate elevation (not ‘out of proportion’),
invasive evaluation is not necessary as, according to
current data, the diagnosis of PH in these conditions
has no additional therapeutic consequences. As a second
step the presence of chronic thromboembolic PH
(CTEPH) has to be evaluated before the diagnosis of
PAH becomes more likely and invasive work-up is
justified.
Symptoms
Patients with PAH can complain of dyspnoea, exercise
intolerance, chest pain, dizziness and syncope, all symp-
toms that are also common in other cardiopulmonary
disorders. For that reason, the diagnosis of PAH is often
delayed. In the advanced stage signs of right heart failure
are present in most of the patients. A decreased peripheral
oxygen saturation due to a decreased cardiac output and in
some cases a right-to-left shunt through a patent foramen
ovale and physiological intrapulmonary shunts can develop.
Furthermore, there can be clinical signs of the associated
disease.
Value of diagnostic tests
The ECG can show signs of right ventricular hypertrophy
(RVH) and right atrial (RA) dilation. On chest X-ray central
pulmonary arterial dilatation and a rarification of the
peripheral blood vessels can be seen (Fig. 2). However,
neither tests have adequate sensitivity and specificity to be
a screening tool.
Echocardiography is the principal screening tool for PH.
However, it has important limitations in accuracy of
estimating pulmonary pressure. Although there are data
showing a good correlation between echocardiographic
findings and invasive measurements, there are also several
studies reporting significant differences [17–19]. Another
limitation is the fact that a measurement of the tricuspid
regurgitation (TR)velocity to estimate PAP is not possible
in a significant proportion of patients due to lack of TR or a
poor acoustic window. In addition to PAP estimation
indirect signs of elevated PAP such as pulmonary regurgi-
tation velocity, acceleration time of the antegrade Doppler
signal across the pulmonary valve and signs of right
ventricular (RV) pressure overload or failure should always
be documented to increase accuracy of the method
(Fig. 3a-d). In patients with symptoms and increased risk
for developing PAH, additional invasive evaluation is
necessary, also in case of normal echocardiographic
findings. Nevertheless echocardiography remains the
non-invasive key investigation and also plays an important
role in classification of PH by excluding or identifying
systolic or diastolic left heart dysfunction and valve disease or
congenital heart disease as associated condition and gives
important prognostic information [20, 21]. The presence of
pericardial effusion and a tricuspid annual excursion
(TAPSE) <15 are predictors of worse outcome in PAH.
In pulmonary function tests PAH patients normally show
no or no more than mild restriction or obstruction at
peripheral airway level. But the diffusion capacity of the
lung for carbon monoxide (DLCO) is often severely
reduced. Although a low DLCO can also be the result of
interstitial lung disease or emphysema, the combination of a
very low DLCO with a lack of restriction or obstruction is
very suspicious for PAH conditions, especially PVOD and
collagen vascular disease.
In cardiopulmonary exercise tests PAH patients can
show reduction in VO2max and increase in ventilatory
inefficiency (VE/VCO2); furthermore early lactate acidosis,
decreased end-expiratory CO2 and reduced O2 pulse are
common, but none of those changes are specific for PAH.
However, exercise tests have an important role in the
f o l l o w - u pi nP A Hp a t i e n t sa sV O 2m a xa n da l s oa
simple 6-minute walk test (6 MWD) are important
prognostic markers [22]. A peak VO2 <12 ml/min/kg or a
6 MWD <300 m are predictors of clinical decline and
mortality. Shah et al. could show an independent relation
between exercise capacity and PVR, RA pressure and CO,
the last two reflecting RV function, the strongest predictor
of poor outcome in PAH [23].
516 Neth Heart J (2011) 19:514–522In patients with PH, (HR)CT can show a dilated
proximal pulmonary artery, abnormal pulmonary vessels,
RV dilation and abnormal septal position. It can rule out
emphysema or interstitial lung disease and can give
important information for the diagnosis of PVOD [24].
CT angiography is necessary if a ventilation/perfusion scan
can not sufficiently rule out thromboembolic lung disease.
MRI can not serve as a screening tool for PAH due to the
insufficient accuracy of estimating pulmonary pressure and
the availability of MRI. However, MRI is an important
upcoming diagnostic tool in PAH as it is currently
considered to be the non-invasive gold standard for
evaluation of the right ventricle [25]. It allows a distinct
visualisation of the right ventricle, evaluation of RV mass,
septal bowing as a consequence of RV pressure or volume
overload, and systolic and diastolic volumes of the right
and left ventricle, which gives important information not
only about compromised RV function but also about
interventricular dependency (Fig. 4). As decline of RV
function is a key predictor of mortality, MRI provides
Fig. 1 Diagnostic algorithm
for PH (ESC guidelines PH(1)
Neth Heart J (2011) 19:514–522 517essential information about the stage of the disease and
supports therapeutic decisions.
Right heart catheterisation (RHC) is always required to
confirm the diagnosis of PAH and to assess haemodynam-
ics. In the same procedure vasoreactivity tests should be
performed, which are indicated in PAH to identify patients
who might benefit from long-term therapy with calcium
channel blockers. The procedure has a low risk in
experienced centres (mortality 0.055%) [26]. The agent of
choice in acute vasoreactivity testing is inhaled nitric oxide
(NO), because it has the lowest risk profile. Epoprostenol or
adenosine intravenously can be used as an alternative.
Response to a vasoreactivity test is defined as decrease of
the mean PAP by ≥10 mmHg reaching a value ≤40 mmHg
without decreasing cardiac output [27]. RHC should be
repeated in patients with clinical deterioration for the
evaluation of treatment escalation or timing of (heart)lung
transplantation. Right atrial pressure and cardiac output are
established prognostic markers.
BNP/NT-proBNP levels reflect the severity of RV
dysfunction and are predictors of outcome. A NT-proBNP
Fig. 3 a-d echocardiography in a patient with portopulmonary PAH.
a and b apical four-chamber view and parasternal short-axis view
showing an enlarged and hypertrophic right ventricle and a flattened
interventricular septum, compromising the left ventricle. Pericardial
effusion is present, a predictor of worse outcome. c and d Significant
tricuspid regurgitation with a flow velocity of 4.23 m/sec in
accordance with a pulmonary artery pressure of 71.4 mmHg+right
atrial pressure)
Fig. 2 Chest X-ray of a PAH patient showing a prominent pulmonary
artery and enlargement of the right atrium and right ventricle. There is
also mild rarification of peripheral lung vasculature
518 Neth Heart J (2011) 19:514–522cut-off point at 1400 pg/mL was predictive of a 3-year
outcome in 55 patients with severe precapillary PH [28].
But larger studies are needed to confirm or optimise the cut-
off value for different subgroups of PAH.
Treatment
General measurements
All patients with PAH should be treated in multidisciplinary
teams in expert centres [1]. Treatment of the associated
disease should be optimised in cooperation with the treating
specialists. There are several restrictions and potential life-
threatening conditions to avoid. It cannot be stressed enough
that general precautionary measurements in daily life have an
important impact on survival in PAH. Pregnancy is contra-
indicated in all PAH patients. Patients should avoid staying
at high altitude level (>1500 m). PAH is a high-risk factor for
surgery. Surgery, if unavoidable, should therefore take place
in cooperation with a PH centre. Fluid restriction and
diuretics are indicated when right heart failure develops.
Beta-blockers are not indicated. Calcium channel blockers
(CCB) are only allowed in patients who have responded to
invasive vasoreactivity testing. Anticoagulation is indicated
(INR 2.0–3.0) to prevent in-situ thrombosis in IPAH,
heritable PAH, and PAH due to anorexigens. However, it
should be weighted against the risk of bleeding in other PAH
subgroups and individually [1, 29]. Oxygen therapy is
advised in case of pO2 <8 kPa (60 mmHg) [1].
Advanced PAH medication
In the last decade advanced medication targeting the
pulmonary vascular tone has become available and could
essentially contribute to a better outcome in patients with
PAH. Currently there are three groups with different
pathophysiological pathways available: prostanoids, endo-
thelin receptor antagonists (ERA) and phosphodiasterase-5
inhibitors (PDE-5 inhibitors). All three groups reached the
status of established PAH therapy. However, most of the
studies were conducted in patients with IPAH, heritable
PAH, drug-induced PAH and PAH associated with connec-
tive tissue disease. The data are limited in CHD-PAH.
There is one randomised study available for the subgroup
with Eisenmenger physiology[30] and PAH-CHD patients
are sometimes small subgroups in larger randomized
studies with PAH. Data are even more limited in PAH
associated with HIV [31], portopulmonary PAH [32],
haemolytic anaemia and schistosomiasis. Randomised
studies are lacking in these subgroups. There is currently
not enough evidence that advanced PAH drugs improve
outcome in other forms of PH than PAH (group 2 to 5 of
PH classification).
Prostanoids
As a substitute for the lack of endogenous prostacyclin,
which is produced by endothelial cells, prostacyclin (epo-
prostenol) was introduced 1984 as a continuous infusion for
the treatment of PAH. In 1996, before the era of oral PAH
drugs began, a randomised study could document that the
use of epoprostenol improved clinical status, haemodynam-
ics and survival compared with conventional therapy [33].
For use in patients with functional class IV it is still the
only drug with a level of evidence A and therefore the drug
of choice. An important disadvantage is the need for
continuous administration of the drug through a central
venous line with a portable infusion pump. Catheter-related
complications (infection, thrombosis) as well as emergency
situations with rebound PH caused by accidental discontin-
uation of the drug are often reported. In the meantime
prostacyclin analogues have been developed which can be
administered intravenously, subcutaneously, orally or by
inhalation. Two of them are currently available in the
Netherlands: trepostinil and iloprost. Trepostinil has a
longer half-life and can be administered subcutaneously.
In a placebo-controlled study improvement of symptoms
and haemodynamics could be shown [34]. However, the
subcutaneous administration is associated with pain at the
injection site in 85% of the cases and requires frequent
change of injection sites, local anaesthetics or even
discontinuation of the drug. Iloprost can be administered
through inhalation and acts selectively on pulmonary artery
vessels in ventilated regions of the lung. A randomised trial
showed significant clinical improvement compared with
placebo [35]. However, iloprost has to be inhaled 6–9 times
per day (30 min per session) to reach an effect comparable
with other prostanoids.
Fig. 4 Cardiac MRI of a PAH patient showing a wide and
hypertrophied right ventricle and flattening of the intraventricular
septum. With late enhancement myocardial fibrosis can be docu-
mented in areas where the right ventricle inserts the septum
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PAH is characterised by elevated plasma and tissue levels
of endothelin-1, a strong vasoconstrictor and inductor of
smooth muscle cell proliferation. It acts by binding to
endothelin receptors (ETA and ETB). Bosentan is a dual
receptor antagonist, blocking both receptors. Several rand-
omised clinical studies show that bosentan has beneficial
effects on exercise capacity, haemodynamics and the time
to clinical worsening [36–39]. The drug is usually well
tolerated. One important side effect is an increase of liver
enzyme levels in approximately 10% of the cases. So
treatment with bosentan requires monthly monitoring of
liver function. Sometimes dose reduction and in rare cases
discontinuation of the drug is necessary.
Ambrisentan, a selective ETA receptor antagonist, is also
associated with a significant clinical improvement in
randomised trials [40], although data about ambrisentan
are more limited. Of note, in studies with ambrisentan only
very few patients presented with an increase of liver
enzymes. Still, monitoring of liver function tests is
mandatory in all patients treated with ERA. Another
selective ETA receptor antagonist, sitaxentan, was with-
drawn from the market in December 2010 because of
complications caused by increase of liver enzymes. Other
side effects of ERA can be peripheral oedema, and
pharmacological interaction for instance with coumarins.
Furthermore, pregnancy is contraindicated because of the
potential teratogenicy of ERA.
PDE-5 inhibitors
The inhibition of phosphodiesterase-5 causes an increase of
cyclic-GMP, which induces vasodilation and inhibits
pulmonary artery remodelling. It also has a positive
inotropic effect on the hypertrophic right ventricle. The
first PDE-5 inhibitor approved for treatment of PAH was
sildenafil. A placebo-controlled trial [41] shows a signifi-
cant but not dose-dependent increase in the 6 MWD for
sildenafil (in an oral dose of 20, 40 and 80 mg 3 times per
Table 2 Medication for advanced PAH currently available in the Netherlands
Substance class Drug Special consideration
ERA Bosentan (Tracleer) Can cause elevated liver function tests, (Bosentan>Ambrisentan)
Monthly lab monitoring indicated
Ambrisentan (Volibris)
PDE-5-inhibitor Sildenafil (Revatio) No combination with No-donors, nitrates.
Can induce visual disturbances
Tadalafil (Adcirca, Cialis)
Prostanoids Iloprost inhaled (Ventavis) 6–9 inhalations/day
Trepostinil (Remodulin) Continuous subcutaneous infusion
Pain at injection site is very common
Epoprostenol i.v. (Flolan) Central venous line necessary with risk of infection and thromboembolism
Relatively contraindicated in patients with right-to-left shunts
Prostanoids general: flush, hypotension, headache
Ca-channel blockers Diltiazem Only indicated in patients who respond to acute vasoractivity tests
Amlodipine
Table 3 Parameters with estab-
lished importance for assessing
disease severity, stability and
prognosis in PAH; ESC guide-
lines PH [1]
6 MWD 6 minute walk distance,
PE pericardial effusion, TAPSE
tricuspid annual systolic excur-
sion, RAP right atrial pressure,
CI cardiac index
Better prognosis Determinants of prognosis Worse prognosis
No Clinical evidence of RV failure Yes
Slow Rate of progression of symptoms Rapid
No Syncope Yes
I,II WHO-FC IV
>500 m 6MWD <300 m
Peak VO2 >15 ml/min/kg Cardiopulmonary exercise test Peak VO2 <12 ml/min/kg
Normal or near-normal BNP/NT-proBNP Very elevated and rising
No PE, TAPSE >20 mm Echocardiographic findings PE, TAPSE <15 mm
RAP <8 mmHg, Haemodynamics RAP>15 mmHg
CI ≥2.5 l/min/m2 CI≤2.0 l/min/m2
520 Neth Heart J (2011) 19:514–522day respectively) in 278 patients with mostly IPAH. A
randomisedcontrolledtrialwithtadalafilshowsimprovement
in 6 MWD and a slight increase in time to clinical worsening
compared with a placebo group [42]. Tadalafil was approved
in 2009 and can be administered in a single oral daily dose.
PDE-5 inhibitors must not be combined with other NO
donors such as nitrates, because this combination can induce
extreme hypotension. Furthermore, the use of protease
inhibitors such as ritonavir and indinavir can increase the
bioactivity of PDE-5 inhibitors, which has to be taken into
account when treating patients with PAH associated with
HIV infection. Other possible side effects are visual
disorders (such as photosensitivity and colour changes),
flushes, and headache and muscle pain.
Follow-up
Diagnosis of PAH and initiation of therapy with advanced
PAH medication has to be the beginning of an intensive and
well-structured care. Depending on the WHO functional class
initial therapy normally starts with one medical substance
according to the guidelines [1]. The medication for advanced
PAH that is available in the Netherlands is listed in Table 2.
Short-term follow-up is indicated (every 3–4 months).
Depending on clinical condition and diagnostic tests, which
consist of laboratory tests, exercise tests, echocardiography
and, if necessary right heart catheterisation, medical therapy
has to be increased when treatment goals are not reached [43,
44] (see criteria of stable or unstable disease: Table 3). In
addition C-reactive protein and heart rate, two simply
obtainable parameters, have recently been shown to contain
prognostic information in PAH [45, 46] and can be used
alongside. Several forms of combination therapy are estab-
lished [38, 47, 48] or are currently under investigation.
Combination therapy as initial therapy has been discussed,
but is not yet an established therapy. If a PAH patient is not
responding or even deteriorating under PAH medication the
diagnosis of PVOD should be considered, especially, when
the patient tends to develop lung oedema under therapy.
In patients who are unstable despite optimised combina-
tion therapy atrioseptostomy can be considered. After
passing the atrium septum, by using the Brockenbrough
procedure, a small right-to-left shunt is created by balloon
inflation to unload the right ventricle at the cost of lower
arterial saturation. The size of the shunt is guided by arterial
saturation. A pre-interventional RA pressure >20 mmHg
and arterial saturation <90% are contraindications for the
procedure, which should only be performed in experienced
centres considering the high risk [49].
Despite the good results of disease stabilisation with
medical combination therapy, PAH remains a disease with a
poor prognosis. Listing for lung or heart/lung transplantation
in time and close cooperation with a transplantation centre is
essential. A recent study shows that mortality of PAH patients
on the waiting list for lung transplantation is disproportionate,
whereas the outcome after transplantation is similar to other
conditions (COPD, idiopathic pulmonary fibrosis) [50].
Conclusion
Despite the success of disease stabilisation with medical
therapy, targeting the pulmonary vascular tone, PAH is still a
conditionwith apoor prognosis.Earlydiagnosis, goal-oriented
treatment in PH expert centres, development of new drugs and
timely listing for lung transplantation will hopefully further
improve outcome in this heterogeneous group of patients.
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